Table 3.
Classification and distribution of G6PD activities in 551 deficient subjects based on the WHO guideline. Note: Data were shown as number (percentage, mean value of enzyme activity).
| Mutation pattern | WHO class | Actual classification for males with mutation | Actual classification for females with mutation | ||||
|---|---|---|---|---|---|---|---|
| II (≤ 1.6 IU/g Hb) |
III (1.6–9.6 IU/g Hb) |
IV (9.6–24.0 IU/g Hb) |
II (≤ 1.6 IU/g Hb) |
III (1.6–9.6 IU/g Hb) |
IV (9.6–24.0 IU/g Hb) |
||
| c.95 A>G (Gaohe) | II | 45 (91.8, 0.68) | 4 (8.2, 2.2) | 0 | 1 (5.6, 0.60) | 17 (94.4, 6.35) | 0 |
| c.392 G>T (Quingyan) | III | 9 (45, 1.17) | 11 (55, 2.41) | 0 | 1 (7.7, 1.60) | 12 (92.3, 6.19) | 0 |
| c.493 A>G (Taipei) | II | 1 (100, 0.64) | 0 | 0 | 0 | 0 | 0 |
| c.517 T>C (Nankang) | II | 1 (100, 1.39) | 0 | 0 | 0 | 0 | 0 |
| c.592 C>T (Shunde) | II | 0 | 0 | 0 | 0 | 3(100, 6.23) | 0 |
| c.871 G>A (Viangchan) | II | 20 (95.2, 0.48) | 1 (4.8, 2.17) | 0 | 1 (8.3, 0.51) | 10 (83.4, 5.91) | 1 (8.3, 9.72) |
| c.1004 C>A (Fushan) | II | 1 (100, 1.58) | 0 | 0 | 0 | 0 | 0 |
| c.1024 C>T (Chinese-5) | III | 1 (7.1, 1.52) | 13 (92.9, 2.66) | 0 | 1 (7.7, 1.14) | 12 (92.3, 6.20) | 0 |
| c.1311 C>T | – | 4(80.0, 1.11) | 1 (20.0, 8.30) | 0 | 1(16.7, 0.24) | 5 (83.3, 5.50) | |
| c.1360 C>T (Union) | II | 3 (100, 0.68) | 0 | 0 | 0 | 4 (100, 4.93) | 0 |
| c.1376 G>T (Canton) | II | 93 (97.9, 0.44) | 2 (2.1, 1.88) | 0 | 2 (3.8, 0.74) | 49 (94.2, 6.25) | 1 (1.9, 9.98) |
| c.1388 G>A (Kaiping) | II | 122 (96.8, 0.60) | 4 (3.2, 2.42) | 0 | 1 (2.4, 0.01) | 38 (90.5, 6.50) | 3 (7.1, 9.83) |
| All compound mutations | – | 0 | 0 | 0 | 24 (80.0, 0.71) | 6 (20.0, 2.73) | 0 |
| All homozygous mutations | – | 0 | 0 | 0 | 18 (81.8, 0.74) | 4 (18.2, 3.61) | 0 |
Median value (15.96 IU/g Hb) obtained from normal male subjects in our study considered as normal G6PD activity. The residual enzyme activity ≤ 1.6 IU/g Hb (10% of normal) was grouped into class II (severe deficiency); between 1.6–9.6 IU/g Hb (10–60% of normal) class III (moderate deficiency), and between 9.6–24.0 IU/g Hb into class IV (normal). Class I, which includes severely deficient variants associated with chronic nonspherocytic hemolytic anemia (CNSHA), was not considered in the study. Class V was not presented in the table because all residual enzyme activities in subjects with mutation detected were no more than 150% of normal.